Cardiology Research

Researching cardiology conditions and treatment options

Palmetto Health-USC Cardiology providers are actively engaged in researching conditions of the heart, arteries and veins in laboratory and clinical research programs.

Our cardiologists are also continually studying new diagnosis and treatment options for people with cardiovascular disease. Clnical trial research includes studies in structural and ischemic heart disease, heart failure and vascular diseases.

Current clinical trials


Atrial fibrillation 


AAD: Comparison of Recurrence of Atrial Fibrillation Post Cryoballon Ablation during the 90-day Blanking Period-with and without Anti-Arrhythmic Drug Therapy

Brief summary: A pilot study monitoring safety and recurrence of paroxysmal atrial fibrillation after 1st cryo-balloon ablation with and without antiarrhythmic drug therapy during the 90-day blanking period examined with adverse event monitoring and Cardiovascular Implantable Electronic Devices (CIEDs).

Main Criteria for inclusion: 18 to 80 years old, drug refractory and recurrent paroxysmal atrial fibrillation, meets standard medical criteria for cryo-balloon ablation to treat Paroxysmal Atrial Fibrillation, prior cardiovascular implantable electronic device

For more information, visit: https://clinicaltrials.gov/ct2/show/NCT02913014?term=NCT02913014&rank=1

Heart failure


EMPEROR-Preserved:
A Phase III Randomized, Double-blind Trial to Evaluate Efficacy and Safety of Once Daily Empagliflozin 10 mg Compared to Placebo, in Patients with Chronic Heart Failure with Preserved Ejection Fraction (HFpEF)

Brief Summary: A phase three, double blind study with the aim to evaluate the efficacy and safety of Empagliflozin 10 mg versus placebo in patients with heart failure with preserved ejection fraction. This is a multicenter trial with the overall goal to enroll 4126 patients.

Main Criteria for inclusion: 18 years or older, chronic heart failure with ejection fraction > 40%

For more information, visit: https://clinicaltrials.gov/ct2/show/NCT03057951?term=NCT03057951&rank=1


PREVENT II:
Prevention of Non-Surgical Bleeding by Management of HeartMate II Patients Without Antiplatelet Therapy

Brief Summary: A phase four, double blind study with the aim to evaluate whether patients implanted with a HeatMate II (HMII) Left Ventricle Assist Device (LVAD) on warfarin (Coumadin) alone have a lower rate of non-surgical bleeding compared to HM II patients on both warfarin and aspirin. This is a multicenter trial with the goal to overall enroll 350 patients.

Main Criteria for inclusion: 50 years or older, will be receiving HM II as first LVAD

For more information, visit: https://clinicaltrials.gov/ct2/show/NCT02836652?term=NCT02836652&rank=1


QP ExCELs:
Sentus QP - Extended CRT Evaluation with Quadripolar Left Ventricular Leads

Brief Summary: An interventional study to confirm the safety and efficacy of the BIOTRONIK Sentus OTW QP left ventricular leads. This is study is a multicenter trial with the overall goal to enroll 1754 patients.

Main Criteria for inclusion: 18 years or older, implantation of ICD or pacemaker using a BIOTRONIK CRT-D system with IS4 LV port and Sentus QP LV lead

For more information, visit: https://clinicaltrials.gov/ct2/show/NCT02290028?term=NCT02290028&rank=1

Pulmonary hypertension


SOPRANO:
Clinical Study to Assess the Efficacy and Safety of Macitentan in Patients with Pulmonary Hypertension After Left Ventricular Assist Device Implantation

Brief Summary: A phase 2 double blind study with the aim to evaluate the effect of Macitentan 10 mg on pulmonary vascular resistance (PVR) compared to placebo in subjects with pulmonary hypertension (PH) after left ventricular assist device (LVAD) implantation. This is a multicenter trial with the overall goal to enroll 78 patients.

Main Criteria for inclusion: 18 years or older, implantation of LVAD within past 90 days

For more information, visit: https://clinicaltrials.gov/ct2/show/NCT02554903?term=NCT02554903&rank=1

Our affiliate system

We are building one organization with affiliates in two regions. Our parent company, now known as Prisma Health, supports both affiliates with overall direction and leadership as we continue to align. We will soon share one brand across the entire organization to better reflect this. Palmetto Health-USC Medical Group will be rebranded in late 2019 and will continue to operate as a joint venture between the Midlands affiliate and the USC School of Medicine.

Learn More
We are becoming Prisma Health-USC Medical Group